Teva Pharmaceutical Industries
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Teva Pharmaceutical Industries' revenue will expand 20.6% and EPS will increase 16.4%.
The average estimate for revenue is $5.08 billion. On the bottom line, the average EPS estimate is $1.28.
Last quarter, Teva Pharmaceutical Industries logged revenue of $5.10 billion. GAAP reported sales were 25% higher than the prior-year quarter's $4.08 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.47. GAAP EPS of $0.97 for Q1 were 15% higher than the prior-year quarter's $0.84 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 52.2%, 170 basis points worse than the prior-year quarter. Operating margin was 22.2%, about the same as the prior-year quarter. Net margin was 16.8%, 190 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $20.59 billion. The average EPS estimate is $5.38.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,484 members out of 2,553 rating the stock outperform, and 69 members rating it underperform. Among 519 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 513 give Teva Pharmaceutical Industries a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $53.48.
- Add Teva Pharmaceutical Industries to My Watchlist.